Abstract. Previous studies have demonstrated some significant differences in HLA allele frequencies in leukemic patients and normal subjects. In Moroccan leukemic patients, the frequency of HLA alleles has not already been determined. We have analyzed HLA class I and class II alleles and haplotypes in 62 Moroccan leukemic patients and 98 unrelated normal subjects using PCR-SSO method. Significant positive association with the disease, in patients compared to controls, was found for three alleles: HLA-B*44 (12.7% vs 6.6%; p = 0.02), HLA-DRB1*13 (11.8% vs 9.79%; p = 0.04) and HLA-DRB *01 (4.5% vs 10.7%; p = 0.05). Regarding haplotypes analysis, no significant association was found between patients and control groups. It is suggested that HLA-B*44 and HLA-DRB1*13 alleles may play a presumptive predisposing factor while the HLA-DRB*01 allele could be a protective genetic factor against leukemia.
The major histocompatibility complex (MHC) is a polymorphic and polygenic system that contains the loci for genes encoding class I and class II HLA alloantigens. These genes are closely linked to each other on the short arm of human chromosome 6. HLA complex encompasses some four million base pairs of DNA. It encodes for the HLA-A, B, C (class I), and HLA-DR, DQ, and DP (class II) antigens. The function of the MHC in immune responsiveness is also reflected in its genetic polymorphism. In addition to the control of transplant acceptance and immune responsiveness, it has been recognized for many years that the MHC in the human plays an important role in the etiology of a number of diseases [1] . Numerous studies have been performed to date to study the HLA polymorphism in different populations and ethnic groups [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Practical applications of HLA antigens include the probability of finding donors for stem cell transplantation [13] and the investigation of HLA and disease associations like leukemia [14] , which is a malignancy of the hematopoietic system characterized by diffuse replacement of the bone marrow by neoplastic cells. In acute leukemia lymphoblastic (ALL) and myeloblastic (AML) the immature hematopoietic cells are increased in the blood, and chronic leukemia lymphoblastic (CLL) and myeloblastic (CML) are characterized by an excess of well-differentiated blood cells. The first HLA study on human leukemia found an increased frequency of HLA-A2 in ALL in 1967 [15] . A second study in ALL extended the first HLA-A*02 association to HLA-A2B12 haplotypical association in 1970 [16] . Others studies have investigated HLA associations in childhood and adult leukemia, some of which included the analysis of HLA-DR/DQ antigens . The largest HLA association study in leukemia was carried out on the International Bone Marrow Transplant Registry data [24, 25] . These studies analyzed a total of 1834 patients with ALL, AML, and CML treated between 1969 and 1985. These studies showed that HLACw3 and -Cw4 are both susceptibility markers for all the three major leukemia. HLA-DR studies in childhood ALL showed an increase for HLA-DR7 [17] [18] [19] . In one study, adult ALL showed a weak association with HLA-DRB1 *04 [27] and in another CLL was associated with HLA-DRB4*01 [28] . The strongest association in leukemia reported to date has been presented by Seremetis et al. [29] . They used a monoclonal antibody specific for the HVR3 epitope of HLA-DR53 in AML. Also, in the only molecular studies examined the HLA-DRB loci, directly or indirectly, in ALL, CML and CLL, the homozygous genotype for HLA-DRB4*01 had an increased frequency in patients [32] [33] [34] 38] . In childhood ALL, this effect was observed only in male patients [33, 38] . It thus appears that in the HLA-DR region, the HLA-DRB1*04 locus is the susceptibility marker for all major leukemia (AML, ALL, CML, CLL) examined so far.
The frequency of HLA alleles has not been already determined in Moroccan leukemic patients. The aim of this work was to investigate the frequency of HLA class I (HLA-A and HLA-B) and class II (HLA-DRB1) alleles in a group of Moroccan leukemic individuals. We were searching to study the specificity of the association of the HLA system and all major leukemia in the Moroccan patients, and also to define susceptible alleles for leukemia. Our study is serving as begin for further studies on the associations between HLA and leukemia that we are working on with a large number of patients with each type of leukemia.
Material and methods

Population samples
The studied samples consisted of individual and unrelated patients who are BMT candidates, referred from the laboratory of immuno-histocompatibility of Institut Pasteur, Maroc, Casablanca. All individuals were ascertained to be of Moroccan origin. The sample set studied was composed of 98 normal individuals and 62 patients with leukemia.
HLA typing
HLA typing was performed using peripheral blood lymphocytes by molecular technique. DNA was extracted and purified from whole blood collected in 5% EDTA using the salting out procedure proposes by Miller [39] . HLA-A, -B and -DRB1 typing was carried out with polymerase chain reaction and using sequence-specific oligonucleotides (PCR-SSO) of HLA-A, -B and -DRB1 alleles (Line Probe Assay, Innogenetics INNO-LiPA HLA Update).
Statistical analysis
Statistical significance of differences in HLA allele frequencies between patients and controls was determined using χ 2 and Mann-Whitney tests. A p value of 0.05 or less was considered to be significant using InStat version 3.06 (GraphPad Software Inc, CA, 2003). The haplotypes frequencies for the three-loci were calculated using the maximum likelihood method.
article original Results
HLA-A, -B, -DRB1 allele frequencies in a normal population
The polymorphism of HLA-A, -B and -DRB1 genes was investigated in 98 normal individuals. As indicated in tables 1 to 3, HLA-A*02, HLA-B*51, HLA-DRB1*04 and DRB1*07 had the highest frequency in normal population (19.39, 8.16, 15 .82 and 14.29% respectively) and other frequent alleles included HLA-A*01 (12.76%), HLA-B*44 (6.63%), HLA-DRB1*01 (10.71%) and DRB1*13 (9.69%).
HLA-A, -B, -DRB1 allele frequencies in leukemic patients
As demonstrated in table 1, frequencies of HLA-A*02 (20%), -A*03 (11.82%) and -A*26 (4.55%) alleles are higher in patients compared to the control (19.39, 10.2, 1.02% respectively). Table 2 shows that HLA-B*44 (12.73%) was more expressed in patients than the normal individuals (6.63%). For HLA-DRB1 locus (table 3), the most frequent alleles are HLA-DRB1*03 (17.27%), HLA-DRB1*04 (16.55%), -DRB1*13 (11.82%) and -DRB1*15 (10%) observed in patients with leukemia compared to the control (13.78, 15.82%, 9.69 and 7.65% respectively). Whereas some frequencies of HLA-A, -B and -DRB1 alleles were increasing, others are decreasing. The fre- Comparison of the results between the normal population and patients revealed that there is an allelic association between certain HLA-B, -DRB1 antigens leukemia disease. Our results showed that in leukemic patients and in normal individuals, the difference between DRB1*13, DRB1*01 and B*44 was significant (p = 0.04, p = 0.05 and p = 0.02 respectively), but there were moderate difference among DRB1*04 (p = 0.08), *03 (p = 0.1), and *15 (p = 0.09). However, we did not observe any significant difference for the others HLA-A, -B and -DRB1 allele frequencies.
Haplotypes analysis
We also analyzed the rate of expression of the haplotypes associating the three alleles in the patients and the case controls. As showed in table 4, these analyses showed no significant differences in frequencies of haplotypes between patients and controls.
Discussion
The rate of expression of certain HLA alleles and haplotypes is considered among the factors of susceptibility to Our results showed also that HLA-DRB1*01 has decreased in patients. Therefore, this allele may be protective against leukemia, whereas DRB1*03, DRB1*04, DRB1*13 has been moderately increased in patients. It therefore might be considered as susceptible alleles in leukemia disease. HLA-DRB1*04 is the marker of susceptibility for all the types of leukemia AML, ALL, CML, CLL [27] [28] [29] [32] [33] [34] . In a European study, it was revealed the protective effect of HLA-DRB1*04 against the acquisition of CML [41] . Our results showed no association between HLA-A*02 and A*03 alleles and leukemia (p = 0.97 and p = 0.61 respectively). Whereas, the first association study HLAleukemia showed an association between HLA-A*02 to the ALL [15] . Thereafter, others studies in different populations, such as Turkey, also associated HLA-A*02 to the CLL [40] . It has been demonstrated that HLA-A*03 is playing a protective role against CML through its ability to fix the protein b3a2 [41, 42] . We are working on larger studies in purpose to investigate more extensively the role of HLA class I and class II allele in the development of different types of leukemia (ALL, AML, CML and CLL) in Morocco. We are also interested to study the immunological functions of the alleles of resistance or susceptibility involved in the immune response against the proliferation of malignant cells.
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